According to the WHO, preliminary data suggest that the Merck’s vaccine (VSV-EBOV) used during the current outbreaks in Congo was 97.5% efficacious in preventing Ebola infection.
About:
What is it? VSV-EBOV is an Ebola vaccine. Studies suggest that the yet to be licensed vaccine could prevent Ebola infection when used before and also immediately after exposure to the Ebola virus.
Working: The vaccine is based on a virus found in animals called vesicular stomatitis virus (VSV) that is combined with a portion of the protein covering of the Ebola virus. When administered, it induces an immune response against the Ebola virus. It does not contain a live Ebola virus.
Bodies involved: VSV-EBOV has been developed by NewLink Genetics and Merck Vaccines USA in collaboration with the Public Health Agency of Canada.
Dear Student,
You have still not entered your mailing address. Please enter the address where all the study materials will be sent to you. (If applicable).
